九强生物8月12日公告，公司免疫球蛋白A测定试剂盒（胶乳免疫比浊法）获得北京市药品监督管理局 颁发的医疗器械注册证。 本试剂盒用于体外定量测定人尿液､脑脊液中免疫球蛋白A（IgA）的含量｡ 上 述产品取得医疗器械注册证丰富了公司产品类别，有利于增强公司的核心竞争力，对公司未来发展具有 正面影响，但对近期的生产经营和业绩不会产生重大影响｡ ...

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-056 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 北京九强生物技术股份有限公司 董事会 关于取得医疗器械注册证书的公告 2025年8月12日 上述产品取得医疗器械注册证丰富了公司产品类别，有利于增强公司的 核心竞争力，对公司未来发展具有正面影响，但对近期的生产经营和业绩不 会产生重大影响，敬请投资者注意风险。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 1 | 免疫球蛋白 A 测定 试剂盒（胶乳免疫比 | 京 械 注 准 | Ⅱ | 自批准之日起有效期 | 本试剂盒用于体外定量 测定人尿液、脑脊液中 | | --- | --- | --- | --- | --- | --- | | | 浊法） | 20252400761 | | 至 2030 年 08 月 06 日 | 免疫 ...

从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三人年薪分别为284万元、171.11万元、136.67 万元。 从薪酬变动幅度看（仅统计任职两年以上董秘薪资数据），迪瑞医疗的安国柱2024年薪酬降幅最大，同比降幅达25.82%；九强生物的王建民薪酬增幅最大，同比涨幅达172.86%。 责任编辑：公司观察 专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪7 分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有35家上市体外诊断公司，其聘任总体情况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比为1 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有35家上市体外诊断公司，其聘任总体情 况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比 为11%；40岁及以下董秘群体占比为20%。其中，目前仍任职的最年轻的男上市公司董秘年龄33岁，为 爱威科技的袁绘杰；最年轻的女董秘年龄为32岁，为易瑞生物的李文天。 从董秘的学历分布看，拥有本科、硕士学历的董秘占比分别为40%、60%。 从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、 100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三 ...

Group 1 - The core viewpoint of the news is that Jiukang Bio's stock performance shows a significant decline in its earnings compared to the industry average, indicating potential investment concerns [1] - Jiukang Bio's closing price on August 4 was 15.15 yuan, with a PE ratio of 17.94, marking a new low in 72 days and a total market capitalization of 8.883 billion yuan [1] - The company ranks 39th in the medical device industry, which has an average PE ratio of 54.32 and a median of 38.11 [1] Group 2 - In terms of capital flow, Jiukang Bio experienced a net inflow of 16.9344 million yuan on August 4, but overall, there was a net outflow of 3.0466 million yuan over the past five days [1] - The main business of Jiukang Bio includes research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1] - The latest financial report for Q1 2025 shows Jiukang Bio achieved revenue of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99%, with a gross margin of 80.84% [1]

Group 1 - The stock price of Jiukang Bio (300406) closed at 14.81 yuan on July 25, 2025, with an increase of 0.41% and a turnover rate of 2.05% [1] - On July 25, 2025, the net inflow of main funds into Jiukang Bio was 7.4841 million yuan, while retail investors experienced a net outflow of 8.6644 million yuan [2][4] - Jiukang Bio announced the issuance of convertible bonds totaling 1.139 billion yuan, with an initial conversion price set at 17.63 yuan per share [2] Group 2 - The company completed the repurchase and cancellation of 2,017,966 restricted shares, reducing the total share capital to 586,308,628 shares [2][4] - The conversion price of the "Jiukang Convertible Bonds" was adjusted from 16.95 yuan to 16.98 yuan per share, effective from July 23, 2025 [2][4] - CICC stated that the recent actions would not impact the company's daily operations or debt repayment capabilities [2]

Core Viewpoint - The report outlines the key details regarding the issuance and management of the convertible bonds by Beijing Jiukang Biotechnology Co., Ltd., including the bond's characteristics, issuance approval, and adjustments to the conversion price due to stock repurchase and dividend distributions [3][4][10]. Group 1: Bond Issuance Details - The total issuance amount of the convertible bonds is RMB 1.139 billion, with a total of 11,390,000 bonds issued at a face value of RMB 100 each [4][5]. - The bond has a maturity period of 6 years, starting from June 30, 2022, to June 29, 2028 [5]. - The interest rates for the bond are structured to increase over the years, starting from 0.3% in the first year to 3.0% in the sixth year [5][6]. Group 2: Conversion Price Adjustments - The initial conversion price of the bonds was set at RMB 17.63 per share, which was adjusted to RMB 17.53 following a cash dividend distribution [12]. - Subsequent adjustments to the conversion price were made, bringing it down to RMB 17.55 after a stock repurchase and further to RMB 17.35 after another dividend distribution [14][16]. - The latest adjustment resulted in a conversion price of RMB 16.98, effective from July 23, 2025, due to additional stock repurchases [20]. Group 3: Credit Rating and Management - The bonds have been rated AA- by Zhongzheng Pengyuan Credit Rating Co., Ltd., with a stable outlook [15]. - The management of the bonds is overseen by China International Capital Corporation, which is responsible for ensuring the protection of bondholders' interests [20].

股票代码：300406 股票简称：九强生物 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 公开发行可转换公司债券 第二次临时受托管理事务报告 （2025 年度） 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为中金公司所作的承诺 或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为，中金公 司不承担任何责任。 1 中金公司作为 2022 年北京九强生物技术股份有限公司（以下简称"发行人"、 "公司"或"九强生物"）创业板向不特定对象发行可转换公司债券（债券简称： 九强转债，债券代码：123150，以下简称"本期债券"）的保荐机构和联席主承 销商，持续密切关注对债券持有人权益有重大影响的事项。根据《公司债券发行 与交易管理办法》《公司债券受托管理人执业行为准则》《可转换公司债券管理办 法》等相关规定、本期债券《受托管理协议》的约定、发行人于 2025 年 7 月 22 日披露的《北京九强生物技术股份有限公司关于部分限制性股票回购注销完成的 公告》（公告编号：2025-054）及《北京九强生物技术股份有限 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Jiukang Biological Technology Co., Ltd., indicating a decline in revenue and profit in the latest quarterly report [1][2] - As of July 24, Jiukang's stock closed at 14.75 yuan, with a PE ratio of 17.46, marking a 64-day low, and a total market capitalization of 8.648 billion yuan [1] - The average PE ratio for the medical device industry is 54.55, with a median of 37.54, positioning Jiukang at 38th among its peers [1][2] Group 2 - In the first quarter of 2025, Jiukang reported revenue of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99%, with a gross margin of 80.84% [1] - The company specializes in biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics, with key products including in vitro diagnostic reagents and instruments [1] - As of the first quarter of 2025, seven institutions held shares in Jiukang, with a total of 9.9565 million shares valued at 141 million yuan [1]

Core Insights - The in vitro diagnostics (IVD) industry is a crucial component of modern healthcare, providing essential data for disease prevention, diagnosis, and treatment through various testing methods [1][5][10] - China's IVD market has surpassed 120 billion yuan in 2024, with a projected growth to 165 billion yuan by 2029, reflecting a compound annual growth rate of 5-8% [1][10][19] - The industry is experiencing significant domestic substitution, with over 80% of Class III diagnostic products being domestically produced, while the share of imported products has decreased from 29.3% to 19.5% from 2021 to 2024 [1][14] Industry Overview - IVD encompasses several testing methods, including biochemical, immunological, molecular, microbiological, blood diagnostics, and point-of-care testing (POCT) [2][5] - The industry is transitioning from scale expansion to high-quality development, driven by government policies and technological innovations [5][21] Policy and Regulatory Environment - Recent government policies, such as the "14th Five-Year Plan for Bioeconomic Development" and the "Comprehensive Action Plan for Improving Medical Quality (2023-2025)," provide a strong impetus for the IVD industry [5][7] - The introduction of the "List of In Vitro Diagnostic Reagents Exempt from Clinical Trials (2025)" has expanded the range of products available in the market [7] Market Dynamics - The IVD industry is characterized by a multi-tiered market structure, with foreign giants dominating the high-end market and domestic leaders gradually increasing their market share [15][19] - The competitive landscape is evolving, with leading companies like Mindray Medical and New Industry Bio showing strong performance, while former leaders in COVID-19 testing, such as Da An Gene and BGI, are seeking business transformation [19][20] Growth Trends - The IVD industry is witnessing a shift towards precision and intelligent diagnostics, with advancements in molecular diagnostics, chemiluminescence, and POCT technologies [21][22] - The integration of AI and big data is enhancing diagnostic efficiency, while the demand for home health management and early cancer screening is rising due to an aging population [21][24] Competitive Landscape - The first tier of the market is dominated by international giants like Roche and Abbott, while domestic leaders such as Mindray and New Industry Bio are gaining traction in immunological and molecular diagnostics [15][19] - The market is seeing increased consolidation, with leading companies acquiring smaller firms to enhance their technological capabilities [23] Registration and Product Development - The registration of IVD products has been robust, with a compound annual growth rate of 25.3% from 2021 to 2024, indicating a vibrant development in the sector [14] - In 2024, the registration of domestic Class III diagnostic products reached 533, accounting for 80.5% of total IVD product registrations [14]